Cinacalcet therapy for achievement of the NKF/K-DOQITM clinical practice guidelines for bone and mineral metabolism in individuals under regular hemodialysis

Introduction: Cinacalcet (CNL) suppresses the secretion of parathyroid hormone (PTH). Objective: To consider the effect of CNL administration on achievement of K/DOQITM (Kidney Disease Outcomes Quality Initiative) targets in a group of hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). Patients and Methods: Patients undergoing HD who had initiated CNL enrolled in the study. Data were collected at the baseline and after 12 months. This data consisted of serum calcium (Ca), phosphorus (P), intact PTH (iPTH), proportion of calcium in dialysate, administered doses of CNL and proportion of administered phosphate binders and proportion of patients attaining K/DOQITM targets were gathered. Results: Twenty HD patients enrolled in the study. The proportions of individuals attaining K/DOQITM targets at month 12 were 35% for iPTH, 65% for P, 60% for Ca and 80% for Ca×P product, compared with 0%, 45%, 55% and 50% at the baseline respectively. Around 35% of individuals had attained the combined K/DOQITM targets for Ca, P and iPTH compared with 0% at the starting point. Conclusion: CNL ameliorates attainment of K/DOQITM targets in individuals with SHPT. This result is consistent with findings from other studies.